|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Vir Biotechnology, Inc. (VIR) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
127,390,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$246,341 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
167,399 |
167,399 |
965,615 |
6,020,154 |
| Total Sell Value |
$1,671,921 |
$1,671,921 |
$22,530,609 |
$154,253,203 |
| Total People Sold |
5 |
5 |
9 |
11 |
| Total Sell Transactions |
10 |
10 |
26 |
124 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bybee Clinton |
10% Owner |
– – • |
2022-06-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(500,000) |
10,112,845 |
|
- |
|
| Bybee Clinton |
10% Owner |
– – • |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
17,502 |
43,015 |
|
- |
|
| Bybee Clinton |
10% Owner |
– – • |
2022-06-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(500,000) |
10,395,064 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
29,173 |
283,124 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2022-06-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(500,000) |
10,395,064 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2022-05-24 |
4 |
AS |
$23.82 |
$80,369 |
D/D |
(3,374) |
1,506,494 |
|
- |
|
| Ramasastry Saira |
Director |
– • – |
2022-05-24 |
4 |
AS |
$23.82 |
$40,184 |
D/D |
(1,687) |
8,092 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
115,147 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
1,509,868 |
|
- |
|
| Hatfield Jeffrey S. |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
9,779 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
253,951 |
|
- |
|
| Sigal Charles Elliott |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
9,779 |
|
- |
|
| More Robert J |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
42,435 |
|
- |
|
| Ramasastry Saira |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
9,779 |
|
- |
|
| Perez Robert J |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
9,779 |
|
- |
|
| Napolitano Janet |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
9,779 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2022-05-09 |
4 |
AS |
$20.62 |
$299,835 |
D/D |
(14,541) |
1,503,463 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2022-04-28 |
4 |
AS |
$20.74 |
$374,424 |
D/D |
(17,915) |
1,518,004 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2022-04-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,777 |
148,991 |
|
- |
|
| Hanly Ann M. |
Chief Technology Officer |
• – – |
2022-03-30 |
4 |
S |
$26.24 |
$68,925 |
D/D |
(2,627) |
81,473 |
|
- |
|
| Scangos George A |
President and CEO |
• • – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
111,000 |
223,989 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2022-03-10 |
4 |
OE |
$1.53 |
$13,770 |
D/D |
9,000 |
184,407 |
|
- |
|
| Friedl-Naderer Johanna |
Chief Business Officer, Global |
• – – |
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
90,000 |
|
- |
|
| Horn Howard |
CFO |
• – – |
2022-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
235,384 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2022-02-22 |
4 |
AS |
$30.00 |
$41,250 |
D/D |
(1,375) |
175,407 |
|
- |
|
575 Records found
|
|
Page 10 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
